Behemoth Stack (S4 + LGD-4033 + MK-677) – Product Information
The Behemoth Stack, consisting of S4 Andarine, LGD-4033, and MK-677, is a combination of compounds that may be researched together for their potential effects on muscle growth and performance in subjects. The combination of S4 Andarine, LGD-4033, and MK-677 may have a synergistic effect on muscle development. These compounds have the potential to individually target androgen receptors and growth hormone pathways, potentially leading to increased protein synthesis, muscle hypertrophy, and improved strength gains.
PureRawz sells the Behemoth Stack for research purposes only.
- Behemoth consists of S4 Andarine, LGD-4033, and MK-677.
- Tablets are offered in 2 variants: 40mg S4, 25mg LGD 4033, and 25mg MK-677, totaling 90mg per tablet for 20 tablets or 1800mg in total; and 90mg per tablet for 40 tablets or 3600mg in total.
- Capsules consist of 40mg S4, 25mg LGD 4033, and 25mg MK-677, totaling 90mg per capsule and 3600mg in total.
- The liquid consists of 54mg S4, 33mg LGD 4033, and 33mg MK-677, totaling 120mg per ml and 3600mg in total.
A scientific study published in 2005 examined the effects of Andarine S-4 in the skeletal muscles, bones, and pituitary glands of castrated male rats. A treatment protocol (3 and 10mg/kg S4- Andarine for 8 weeks) was commenced 12 weeks after castration. Andarine (doses 3 and 10 mg/kg) restored soleus muscle mass and strength and levator ani muscle mass to that seen prior to castration or in intact animals.
This makes S4 an investigational selective androgen receptor modulator, for possible treatment of conditions related to muscle wasting, osteoporosis, and benign prostatic hyperplasia (BPH). It has the ability to mimic many of the beneficial pharmacologic effects associated with testosterone.
|Molar Mass||128.3 g/mol-1|
Ligandrol is a novel nonsteroidal oral selective androgen receptor modulator currently being investigated in research as a potential treatment for conditions relating to muscle dystrophy and osteoporosis.
Recent studies investigated the effects of LGD 4033 on muscle tissue in ovariectomized rats. A daily dose of LGD was administered and calculated according to the body weight of each individual rat at the onset of the study. Results and changes were noted as soon as week 2, the control group having weighed significantly less than rats undergoing LGD treatment. This difference remained until the end of the study, irrespective of LGD treatments. Additionally, the LGD treatments resulted in a higher number of capillaries in all muscles studied. Longer randomized trials and research could potentially evaluate its efficacy in improving physical function and health outcomes in select populations.
|Molar Mass||338.253 g·mol−1|
A recent study set out to investigate the effects of MK-677 as a Ghrelin mimetic on body composition and clinical outcomes in healthy older adults. It was found that MK-677 enhanced fluctuating growth hormone secretion and markedly increased fat-free mass over a 12-month period. More extensive research and randomized trials could potentially evaluate its efficacy in improving physical function and health outcomes in select populations.
|Molar Mass||528.67 g·mol−1|
|IUPAC Name||2-amino-2-methyl-N-[1-(1-methylsulfonylspiro[2H indole-3,4′-piperidine]-1′-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide|